In announcing RFK Jr. as having a significant role in healthcare in his administration, he has targeted healthcare in America ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The team’s RNA-LNP approach – described in the journal Cell – works by reprogramming the TME using a sample of the tumour itself, so it can work both as a vaccine to stimulate an immune ...

scientific challenges and regulatory resistance have held back self-amplifying messenger RNA (samRNA) vaccines from taking over the vaccine space. But experts say their time could soon be here. Large ...

[85] Even higher stability and extended shelf life can be expected of RNA vaccines prepared under good manufacturing process conditions. Increasing prevalence of allergy and the resulting ...

It’s a sharp turn in fortune for the chief executive and company veteran who oversaw development and mass production of the novel RNA vaccine, a race against the coronavirus that helped get the ...

The UK is making progress in developing cancer vaccines, but there are still challenges ahead, Chris Baraniuk reports The UK is on its way to becoming a hotbed of cancer vaccine trials. In May this ...

COVID-19 vaccine DNA contamination claims aren't new, but have resurfaced in the wake of a Canadian study that some ...

Many leading pharma and biotechs have invested in messenger RNA (mRNA) technology to develop COVID-19 vaccines and are now exploring their potential in other disease areas (Figure 1). The success ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work ...